NASDAQ:QDEL QuidelOrtho (QDEL) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free QDEL Stock Alerts $39.68 -0.01 (-0.03%) (As of 03:03 PM ET) Add Compare Share Share Today's Range$39.30▼$40.4150-Day Range$38.26▼$49.4852-Week Range$37.78▼$95.02Volume336,018 shsAverage Volume1.00 million shsMarket Capitalization$2.65 billionP/E RatioN/ADividend YieldN/APrice Target$61.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get QuidelOrtho alerts: Email Address QuidelOrtho MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside54.9% Upside$61.60 Price TargetShort InterestHealthy4.05% of Shares Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.11Based on 26 Articles This WeekInsider TradingAcquiring Shares$99,652 Bought Last QuarterProj. Earnings Growth74.56%From $2.28 to $3.98 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.87 out of 5 starsMedical Sector31st out of 908 stocksDiagnostic Substances Industry1st out of 12 stocks 4.0 Analyst's Opinion Consensus RatingQuidelOrtho has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 3 hold ratings, and 2 sell ratings.Amount of Analyst CoverageQuidelOrtho has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.05% of the outstanding shares of QuidelOrtho have been sold short.Short Interest Ratio / Days to CoverQuidelOrtho has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in QuidelOrtho has recently increased by 20.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldQuidelOrtho does not currently pay a dividend.Dividend GrowthQuidelOrtho does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreQuidelOrtho has received a 49.48% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sexually transmitted diseases quick tests", "Lactose intolerance quick tests", and "Respiratory tract infection tests" products. See details.Environmental SustainabilityThe Environmental Impact score for QuidelOrtho is -2.61. Previous Next 2.3 News and Social Media Coverage News SentimentQuidelOrtho has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for QuidelOrtho this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for QDEL on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.MarketBeat Follows8 people have added QuidelOrtho to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, QuidelOrtho insiders have bought more of their company's stock than they have sold. Specifically, they have bought $99,652.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.00% of the stock of QuidelOrtho is held by insiders.Percentage Held by Institutions99.00% of the stock of QuidelOrtho is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for QuidelOrtho are expected to grow by 74.56% in the coming year, from $2.28 to $3.98 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of QuidelOrtho is -248.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of QuidelOrtho is -248.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuidelOrtho has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About QuidelOrtho Stock (NASDAQ:QDEL)QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.Read More QDEL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QDEL Stock News HeadlinesApril 26, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of QuidelOrthoApril 26, 2024 | prnewswire.comQuidelOrtho Corporation f/k/a Quidel Corporation Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - QDELApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 25, 2024 | prnewswire.comROSEN, A RANKED AND LEADING FIRM, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - QDELApril 25, 2024 | prnewswire.comQDEL Investors Have Opportunity to Lead QuidelOrtho Corporation Securities Fraud LawsuitApril 25, 2024 | americanbankingnews.comQuidelOrtho Co. (NASDAQ:QDEL) Given Average Rating of "Hold" by BrokeragesApril 24, 2024 | stockhouse.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against QuidelOrtho Corporation. - QDELApril 23, 2024 | uk.finance.yahoo.comQDEL May 2024 50.000 callApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 23, 2024 | uk.finance.yahoo.comQDEL May 2024 40.000 putApril 23, 2024 | prnewswire.comINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against QuidelOrtho Corporation and Encourages Investors with Losses to Contact the FirmApril 22, 2024 | markets.businessinsider.comSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the FirmApril 22, 2024 | businesswire.comQuidelOrtho Corporation (QDEL) Investor Notice: Robbins LLP Reminds Stockholders of the QuidelOrtho Corporation Shareholder Class ActionApril 22, 2024 | prnewswire.comQDEL LAWSUIT ALERT: Levi & Korsinsky Notifies QuidelOrtho Corporation f/k/a Quidel Corporation Investors of a Class Action Lawsuit and Upcoming DeadlineApril 22, 2024 | prnewswire.comQDEL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that QuidelOrtho Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!April 22, 2024 | americanbankingnews.comQuidelOrtho Co. Forecasted to Earn Q1 2024 Earnings of $0.24 Per Share (NASDAQ:QDEL)April 20, 2024 | americanbankingnews.comQuidelOrtho Co. Forecasted to Post Q3 2024 Earnings of $0.80 Per Share (NASDAQ:QDEL)April 19, 2024 | markets.businessinsider.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the FirmApril 19, 2024 | stockhouse.comLevi & Korsinsky Notifies QuidelOrtho Corporation f/k/a Quidel Corporation Investors of a Class Action Lawsuit and Upcoming Deadline - QDELApril 19, 2024 | stockhouse.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against QuidelOrtho Corporation (QDEL)April 19, 2024 | prnewswire.comClass Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) - June 11, 2024 Deadline to Join - Contact The Gross Law FirmApril 18, 2024 | markets.businessinsider.comINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the FirmApril 18, 2024 | businesswire.comDeadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against QuidelOrtho Corporation (QDEL)April 17, 2024 | markets.businessinsider.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the FirmApril 17, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation (QDEL) InvestorsApril 17, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation (QDEL) InvestorsApril 17, 2024 | finance.yahoo.comQuidelOrtho To Report First Quarter 2024 Financial ResultsSee More Headlines Receive QDEL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for QuidelOrtho and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today4/26/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:QDEL CUSIP74838J10 CIK353569 Webwww.quidel.com Phone(800) 874-1517Fax858-453-4338Employees7,100Year Founded1979Price Target and Rating Average Stock Price Target$61.60 High Stock Price Target$81.00 Low Stock Price Target$37.00 Potential Upside/Downside+55.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E RatioN/A Forward P/E Ratio17.41 P/E GrowthN/ANet Income$-10,100,000.00 Net Margins-0.34% Pretax Margin-0.97% Return on Equity5.54% Return on Assets3.21% Debt Debt-to-Equity Ratio0.45 Current Ratio1.57 Quick Ratio0.88 Sales & Book Value Annual Sales$3.00 billion Price / Sales0.89 Cash Flow$10.70 per share Price / Cash Flow3.71 Book Value$74.92 per share Price / Book0.53Miscellaneous Outstanding Shares66,880,000Free Float66,210,000Market Cap$2.65 billion OptionableOptionable Beta0.11 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Michael S. Iskra (Age 54)Interim CEO, Executive VP & Chief Commercial Officer Comp: $870.93kMr. Robert J. Bujarski J.D. (Age 55)Interim President, Executive VP & COO Comp: $961.26kMr. Joseph M. Busky CPA (Age 56)Chief Financial Officer Comp: $890.63kDr. Werner Kroll Ph.D. (Age 67)Senior Vice President of Research & Development Comp: $1.03MMs. Louise M. Brandy (Age 65)Chief Information Officer Ruben ArguetaDirector of Investor RelationsMs. Michelle A. Hodges J.D. (Age 61)Senior VP, General Counsel & Corporate Secretary Comp: $1.8MMr. William J. Ferenczy (Age 68)Point of Care Business Unit Leader Ms. Tamara A. Ranalli (Age 51)Molecular Diagnostics Business Unit Leader More ExecutivesKey CompetitorsNeogenNASDAQ:NEOGCelldex TherapeuticsNASDAQ:CLDXIntellia TherapeuticsNASDAQ:NTLAMyriad GeneticsNASDAQ:MYGNMeridian BioscienceNASDAQ:VIVOView All CompetitorsInsiders & InstitutionsNew York State Teachers Retirement SystemSold 3,933 shares on 4/25/2024Ownership: 0.083%Amalgamated BankBought 3,014 shares on 4/23/2024Ownership: 0.052%Hunter Perkins Capital Management LLCBought 3,485 shares on 4/23/2024Ownership: 0.022%Louisiana State Employees Retirement SystemBought 300 shares on 4/23/2024Ownership: 0.021%Bfsg LLCBought 2,005 shares on 4/23/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions QDEL Stock Analysis - Frequently Asked Questions Should I buy or sell QuidelOrtho stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for QuidelOrtho in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" QDEL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QDEL, but not buy additional shares or sell existing shares. View QDEL analyst ratings or view top-rated stocks. What is QuidelOrtho's stock price target for 2024? 7 equities research analysts have issued 1-year price objectives for QuidelOrtho's stock. Their QDEL share price targets range from $37.00 to $81.00. On average, they expect the company's stock price to reach $61.60 in the next year. This suggests a possible upside of 54.9% from the stock's current price. View analysts price targets for QDEL or view top-rated stocks among Wall Street analysts. How have QDEL shares performed in 2024? QuidelOrtho's stock was trading at $73.70 at the beginning of the year. Since then, QDEL shares have decreased by 46.1% and is now trading at $39.76. View the best growth stocks for 2024 here. Are investors shorting QuidelOrtho? QuidelOrtho saw a increase in short interest in April. As of April 15th, there was short interest totaling 2,710,000 shares, an increase of 20.4% from the March 31st total of 2,250,000 shares. Based on an average daily trading volume, of 1,110,000 shares, the days-to-cover ratio is presently 2.4 days. View QuidelOrtho's Short Interest. When is QuidelOrtho's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our QDEL earnings forecast. How can I listen to QuidelOrtho's earnings call? QuidelOrtho will be holding an earnings conference call on Wednesday, May 8th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were QuidelOrtho's earnings last quarter? QuidelOrtho Co. (NASDAQ:QDEL) posted its quarterly earnings results on Tuesday, February, 13th. The company reported $1.17 EPS for the quarter, missing the consensus estimate of $2.01 by $0.84. The firm had revenue of $742.60 million for the quarter, compared to analyst estimates of $796.91 million. QuidelOrtho had a negative net margin of 0.34% and a positive trailing twelve-month return on equity of 5.54%. QuidelOrtho's revenue was down 14.3% on a year-over-year basis. During the same quarter last year, the company earned $1.74 earnings per share. What ETFs hold QuidelOrtho's stock? ETFs with the largest weight of QuidelOrtho (NASDAQ:QDEL) stock in their portfolio include Amplify Treatments, Testing and Advancements ETF (GERM), SPDR S&P Health Care Equipment ETF (XHE), First Trust Health Care AlphaDEX Fund (FXH), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Medical Devices ETF (IHI). What guidance has QuidelOrtho issued on next quarter's earnings? QuidelOrtho updated its FY 2024 earnings guidance on Tuesday, February, 13th. The company provided earnings per share (EPS) guidance of 2.400-3.070 for the period, compared to the consensus estimate of 5.070. The company issued revenue guidance of $2.8 billion-$3.1 billion, compared to the consensus revenue estimate of $3.0 billion. What is Doug Bryant's approval rating as QuidelOrtho's CEO? 47 employees have rated QuidelOrtho Chief Executive Officer Doug Bryant on Glassdoor.com. Doug Bryant has an approval rating of 76% among the company's employees. What other stocks do shareholders of QuidelOrtho own? Based on aggregate information from My MarketBeat watchlists, some companies that other QuidelOrtho investors own include NVIDIA (NVDA), DocuSign (DOCU), Tesla (TSLA), PayPal (PYPL), Shopify (SHOP), Block (SQ), Teladoc Health (TDOC), Netflix (NFLX), Advanced Micro Devices (AMD) and Zoom Video Communications (ZM). Who are QuidelOrtho's major shareholders? QuidelOrtho's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Leeward Investments LLC MA (0.33%), Allspring Global Investments Holdings LLC (0.11%), New York State Teachers Retirement System (0.08%), Amalgamated Bank (0.05%), Hunter Perkins Capital Management LLC (0.02%) and Louisiana State Employees Retirement System (0.02%). Insiders that own company stock include Charles P Slacik, Joseph M Busky, Mary Lake Ph D Polan and William J Ferenczy. View institutional ownership trends. How do I buy shares of QuidelOrtho? Shares of QDEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QDEL) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJim Cramer’s “The Biggest Drug Ever”Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding QuidelOrtho Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.